Phoenix A Ho MD
Pediatric Hematology & Oncology at Seattle Children's Hospital
Join to View Full Profile
2324 Eastlake Ave E Ste 500Seattle, WA 98102
Phone+1 206-543-8606
Fax+1 206-987-3946
Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
U Washington Affil Hosps2009
Yale-New Haven Medical CenterResidency, Pediatrics, 2003 - 2006- Yale-New Haven Medical CenterInternship, Pediatrics, 2003 - 2004
Northeast Ohio Medical UniversityClass of 2003
Certifications & Licensure
WA State Medical License 2006 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Feb 01
- Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
- A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsA phase I study of panobinostat in children with relapsed and refractory hematologic malignanciesJohn Goldberg, Maria Luisa Sulis, Julia Glade Bender, Sima Jeha, Rebecca Gardner
Pediatric Hematology and Oncology. 2020-04-27 - 21 citationsA phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemiaC. Michel Zwaan, Stefan Söderhäll, Benoit Brethon, Matteo Luciani, Carmelo Rizzari
British Journal of Haematology. 2019-05-01 - 48 citationsA phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi
Blood. 2018-09-13
Journal Articles
- A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AMLEytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Grant Support
- Exploiting WT1 Alterations in Pediatric AMLSt. Baldrick's Foundation2012–2014
- Exploiting WT1 Genomic Alterations for Target Identification and Minimal Residual Disease Monitoring in Pediatric AMLAlex's Lemonade Stand Foundation2012–2013
- Implications of s-SHIP Expression and SHIP Alterations in AMLNICHD2009–2012
- SHIP and WT1 Alterations as Markers of PI3K/Akt Activation in Pediatric AMLMary Claire Satterly Foundation2011
- Implications of s-SHIP Expression and SHIP Alterations in AMLAmerican Society of Clinical Oncology2009–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
